Regeneron Warns of Slow Praluent Uptake, While Eylea Fuels Growth
This article was originally published in Scrip
Regeneron Pharmaceuticals and big pharma partner Sanofi are distributing free samples of the new cholesterol therapy Praluent (alirocumab) to patients who are awaiting insurance coverage decisions, Regeneron senior vice president of commercial Robert Terifay said during the company's Aug. 4 earnings call, while also warning that this will make it hard to assess uptake of the PCSK9 inhibitor.
You may also be interested in...
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
The global health crisis has presented a chance for the industry to improve its reputation by highlighting the value of its R&D engines. Pharma execs and observers talk to Scrip about why they are optimistic about industry’s chance to regain public trust.
The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.